Skip to main content

elvn-001

·Code: ELVN-001

elvn-001: developed by 1 company · 2 clinical trials tracked.

elvn-001 evidence translation

What we can confirm

What it means

Source-backed records connect elvn-001 to ELVN; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could elvn-001 → ELVN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

CML (Chronic Myelogenous Leukemia); Chronic Myeloid LeukemiaChronic Myeloid Leukemia

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Enliven Therapeutics, Inc. (ELVN)
CML (Chronic Myelogenous Leukemia); Chronic Myeloid Leukemia
Phase 1
Clinical Trials (2)

A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

NCT06787144·Phase 1·ELVN
Recruiting

Primary endpoint: Part 1: Incidence of dose limiting toxicities

Interventionalopen21 targetStarted 2025-01Completion 2028-014 sites · JapanEnliven Therapeutics

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

NCT05304377·Phase 1·ELVN
Recruiting

Primary endpoint: Phase 1a: Incidence of dose limiting toxicities

Interventionalopen250 targetStarted 2022-05Completion 2027-1245 sites · Australia, Belgium, Canada, France…Enliven Therapeutics

Frequently asked questions

Who is developing elvn-001?

elvn-001 is being developed by Enliven Therapeutics, Inc..

How many clinical trials involve elvn-001?

BioSniper tracks 2 clinical trials involving elvn-001.